

Provider Update

AIM to Review Oncology and Oncology Supportive Specialty Drugs for Medical Necessity

Effective **May 1, 2016** all oncology and oncology supportive specialty drugs that require prior authorization for Amerigroup* Community Care Medicare Advantage members will be reviewed for medical necessity through AIM's **ProviderPortal** -- www.providerportal.com -- or by contacting AIM at 1-800-554-0580.

Prior authorization requirements also can be reviewed online at Availity.com.

Providers may be familiar with and participating in the Cancer Care Quality Program administered by AIM. Effective May 1, 2016, CCQP reviews and prior authorizations will be performed by the same review team. The Medicare Advantage Specialty Pharmacy will no longer review oncology and oncology supportive drugs for medical necessity for **individual** Medicare Advantage members effective May 1, 2016.

The Medicare Advantage specialty pharmacy team will continue to conduct oncology and oncology supportive drug prior authorization reviews for Medicare Advantage group-sponsored members. Amerigroup Medicare Advantage member ID cards contain a CMS identifier in the lower right corner of the card. The member is in a group-sponsored plan when the CMS identifier contains eight characters and the last three digits start with an eight (8XX).

58688MUPENMUB 02/08/2016

*In New Mexico, Amerigroup Community Care of New Mexico, Inc. In Texas, Amerigroup members in the Medicaid Rural Service Area are served by Amerigroup Insurance Company; all other Amerigroup members are served by Amerigroup Texas, Inc. In Washington, Amerigroup Washington, Inc.

Amerivantage is a DSNP plan with a Medicare contract and a contract with the State Medicaid program. In New Mexico: Amerivantage is an HMO with a Medicare contract. Enrollment in Amerivantage depends on contract renewal.

